Concepedia

Debu Tripathy

DT

210

Publications

21.2K

Citations

62

H-Index

1996

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of California, San Francisco

University of Southern California

The University of Texas Southwestern Medical Center

Dana-Farber Cancer Institute

Debu Tripathy is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and breast cancer.

ORCID

Top concepts

Publications per year

1996–2025

210

Publications

210

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer

Charles L. Vogel, Melody Cobleigh, Debu Tripathy et al. · Journal of Clinical Oncology · 2002 · 1.8K citations

, , +13

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

José Baselga, Debu Tripathy, John Mendelsohn et al. · Journal of Clinical Oncology · 1996 · 1.4K citations

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Mark D. Pegram, A. Lipton, Daniel F. Hayes et al. · Journal of Clinical Oncology · 1998 · 1.1K citations

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia et al. · New England Journal of Medicine · 2019 · 987 citations · Full text

Rows per page

1–5 of 210